Technical Analysis for PLUR - Pluri Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 200 DMA Support | Bullish | -0.43% | |
| Crossed Above 20 DMA | Bullish | -0.43% | |
| Crossed Above 50 DMA | Bullish | -0.43% | |
| MACD Bullish Signal Line Cross | Bullish | -0.43% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -0.43% | |
| Pocket Pivot | Bullish Swing Setup | -0.43% | |
| Volume Surge | Other | -0.43% | |
| Up 3 Days in a Row | Strength | -0.43% |
| Alert | Time |
|---|---|
| Expansion Pivot Buy Entry | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| 3x Volume Pace | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 06/25/2024
Pluri Inc. Description
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Surgery Stem Cell Cell Therapy Radiation Transplantation Inflammatory Transplantation Medicine Host Disease Acute Respiratory Distress Syndrome Covid 19 Graft Versus Host Disease Cell Therapy Products Surgical Oncology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.56 |
| 52 Week Low | 3.4488 |
| Average Volume | 9,274 |
| 200-Day Moving Average | 5.37 |
| 50-Day Moving Average | 5.67 |
| 20-Day Moving Average | 5.48 |
| 10-Day Moving Average | 5.28 |
| Average True Range | 0.45 |
| RSI (14) | 53.70 |
| ADX | 16.32 |
| +DI | 23.69 |
| -DI | 16.25 |
| Chandelier Exit (Long, 3 ATRs) | 5.00 |
| Chandelier Exit (Short, 3 ATRs) | 5.90 |
| Upper Bollinger Bands | 6.20 |
| Lower Bollinger Band | 4.77 |
| Percent B (%b) | 0.69 |
| BandWidth | 26.01 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.17 |
| MACD Histogram | 0.0449 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.50 | ||||
| Resistance 3 (R3) | 6.50 | 6.26 | 6.37 | ||
| Resistance 2 (R2) | 6.26 | 6.07 | 6.26 | 6.33 | |
| Resistance 1 (R1) | 6.01 | 5.96 | 5.89 | 6.00 | 6.29 |
| Pivot Point | 5.77 | 5.77 | 5.71 | 5.76 | 5.77 |
| Support 1 (S1) | 5.51 | 5.58 | 5.39 | 5.51 | 5.22 |
| Support 2 (S2) | 5.27 | 5.46 | 5.27 | 5.18 | |
| Support 3 (S3) | 5.02 | 5.27 | 5.14 | ||
| Support 4 (S4) | 5.01 |
